Pyxis Oncology FY2030 EPS Forecast Reduced by HC Wainwright

Key Points

• HC Wainwright lowered Pyxis Oncology’s FY2030 EPS forecast to $0.76 from $0.77, while maintaining a “Buy” rating and $7.00 price target.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and $7.50 price target, although several firms have recently reduced ratings or targets.
• Pyxis Oncology shares opened at $2.99, and the company reported a quarterly loss of $0.40 per share, missing the $0.35 consensus estimate. Institutional investors own about 39.1% of the stock.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - HC Wainwright dropped their FY2030 earnings estimates for shares of Pyxis Oncology in a report released on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.76 per share for the year, down from their previous estimate of $0.77. HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.22) per share.

Other equities analysts also recently issued reports about the company. Leerink Partners reduced their target price on Pyxis Oncology from $9.00 to $7.00 and set an "outperform" rating on the stock in a research report on Thursday, July 2nd. Weiss Ratings cut Pyxis Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, June 30th. Wall Street Zen downgraded shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Wedbush assumed coverage on shares of Pyxis Oncology in a research report on Tuesday, May 5th. They issued an "outperform" rating and a $6.00 target price on the stock. Finally, Wells Fargo & Company started coverage on shares of Pyxis Oncology in a research report on Monday, August 3rd. They set an "overweight" rating and a $12.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Pyxis Oncology currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

Pyxis Oncology Stock Down 1.0%

Shares of NASDAQ:PYXS opened at $2.99 on Wednesday. The company has a market cap of $189.43 million, a P/E ratio of -2.12 and a beta of 1.31. Pyxis Oncology has a 52 week low of $1.03 and a 52 week high of $5.55. The business has a fifty day simple moving average of $2.61 and a 200-day simple moving average of $1.99.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05).

Hedge Funds Weigh In On Pyxis Oncology

A number of large investors have recently modified their holdings of the company. Maia Wealth LLC purchased a new stake in shares of Pyxis Oncology during the 4th quarter worth about $25,000. Engineers Gate Manager LP purchased a new position in shares of Pyxis Oncology in the 4th quarter valued at $26,000. Fox Run Management L.L.C. acquired a new position in shares of Pyxis Oncology during the 4th quarter valued at $26,000. XTX Topco Ltd acquired a new stake in Pyxis Oncology in the 2nd quarter valued at $40,000. Finally, LPL Financial LLC lifted its stake in shares of Pyxis Oncology by 150.7% during the fourth quarter. LPL Financial LLC now owns 35,102 shares of the company's stock worth $40,000 after purchasing an additional 21,100 shares in the last quarter. 39.07% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source